Showing 1851-1860 of 2150 results for "".
- Centricity Vision Names Todd Pinkney Chief Commercial Officer; Launches New Campaign for Zepto Cataract Surgical Platformhttps://modernod.com/news/centricity-vision-names-todd-pinkney-chief-commercial-officer-launches-new-campaign-for-zepto-cataract-surgical-platform/2480437/Centricity Vision announced that Todd Pinkney has been named chief commercial officer (CCO) and will lead global commercialization of the Zepto Platform. "We're confident that Zepto will have a huge impact on the cataract surgery market," Mr. Pinkney said.
- I-MED Pharma Set to Launch its Dry Eye Product Portfolio in the UShttps://modernod.com/news/i-med-pharma-set-to-launch-its-innovative-dry-eye-product-portfolio-in-the-us/2480408/I-MED Pharma USA announced it is bringing its dry eye product portfolio to the US market and will sell directly to eye care professionals. The dry eye portfolio includes I-DROP artificial tears, I-LID ’N LASH ocular hy
- Hoya Vision Care and Haag-Streit Partner to Combat Myopiahttps://modernod.com/news/hoya-vision-care-and-haag-streit-partner-to-combat-myopia/2480322/Hoya Vision Care announced a strategic partnership with Haag-Streit to help address the global rise of myopia in children. The global sales and marketing agreement creates a preferred partnership between Hoya Vision Care and Haag-Streit to provide eye care professionals (ECPs) with Lenstar M
- Ludwin Monz Stepping Down as CEO of Carl Zeiss Meditechttps://modernod.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/President and CEO of Carl Zeiss Meditec AG Ludwin Monz, PhD, announced that he will not be accepting another term in office, and will be stepping down from his postion effective December 31, 2021. The supervisory board has appointed Markus Weber, PhD, as the new President and
- Neurolens Names Pierre Bertrand Chief Executive Officerhttps://modernod.com/news/neurolens-names-pierre-bertrand-chief-executive-officer/2480277/Neurolens has named Pierre Bertrand Chief Executive Officer. A senior executive with experience in the eye care space, Mr. Bertrand brings more than 20 years of marketing and strategic expertise to Neurolens. In his role as Chief Executive Officer, Mr. Bertrand will be respons
- Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMDhttps://modernod.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug
- Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sinteticahttps://modernod.com/news/harrow-health-acquires-patented-ophthalmic-surgical-drug-candidate-from-sintetica/2479416/Harrow Health, Inc. announced that it has entered into an agreement with Sintetica to acquire the marketing and supply rights in the U.S. and Canada for AMP 100, a patented ophthalmic surgical drug candidate. When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic interven
- Alcon to Share New Data and Live Booth Presentations at ASCRShttps://modernod.com/news/alcon-to-share-new-data-and-live-booth-presentations-at-ascrs/2479391/Alcon will have approximately 70 abstracts highlighting the benefits of the Alcon Cataract and Refractive suite. A few highlights of the Alcon data include: Robust data demonstrates extremely high level of patient satisfaction and increased spectacle independence for market-leading <
- NovaBay Pharmaceuticals Partners with Harrow Health’s ImprimisRx to Promote Prescription Avenovahttps://modernod.com/news/novabay-pharmaceuticals-partners-with-harrow-healths-imprimisrx-to-promote-prescription-avenova/2479378/NovaBay Pharmaceuticals announced it has partnered with ImprimisRx to promote prescription Avenova. ImprimisRx, a wholly owned subsidiary of Harrow Health, will provide NovaBay with national sales, marketing, and distribution support for its FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bo
- AMA Assigns CPT Code to Software Designed to Treat Adult Amblyopia (Lazy Eye)https://modernod.com/news/ama-assigns-cpt-code-to-software-designed-to-treat-adult-amblyopia-lazy-eye/2479361/RevitalVision announced that its standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical